Coverage of "Biotech ipo" on Cryptopasta: the stories and the context behind them.
Andreessen Horowitz is backing Braveheart Bio's $319 million IPO, signaling a pivot into biotech. Braveheart focuses on heart disease treatment, aiming for a $1.2 billion valuation despite early-stage trials.
July 30, 2026
